Quantitative in vivo comparisons of the Fcγ receptor-dependent agonist activities of different fucosylation variants of an immunoglobulin G antibody

International Immunopharmacology

Volumn 7, Issue 6, 2007, Pages 761-772

  Scallon, Bernard ^a   McCarthy, Stephen ^a   Radewonuk, Jennifer ^a   Cai, Ann ^a   Naso, Michael ^a   Raju, T Shantha ^a   Capocasale, Renold ^a  

^a CENTOCOR INC   (United States)

Author keywords

anti CD3 antibody; Fc receptors; Fucosylation; Immunoglobulin G; T cell activation

Indexed keywords

FC RECEPTOR; FUCOSE; GLYCAN; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; MONOCLONAL ANTIBODY 2C11 HUG1 10; MONOCLONAL ANTIBODY 2C11 HUG1 40; MONOCLONAL ANTIBODY 2C11 HUG1 90; MONOCLONAL ANTIBODY 2C11 HUG1 GNO; MONOCLONAL ANTIBODY 2C11 HUG4 90; MONOCLONAL ANTIBODY 2C11 MUG2A; MONOCLONAL ANTIBODY 2C11 MUG2A ALAALA; MONOCLONAL ANTIBODY CD3; RECOMBINANT RECEPTOR; UNCLASSIFIED DRUG;

AGONIST; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN HEK293; CHIMERA; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG POTENCY; DRUG RECEPTOR BINDING; EMBRYO; FEMALE; FUCOSYLATION; HAMSTRING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN VARIANT; QUANTITATIVE ANALYSIS; RAT; RECEPTOR AFFINITY; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; FUCOSE; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; RECEPTORS, IGG; SPLEEN; T-LYMPHOCYTES;

EID: 34247378189     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2007.01.014     Document Type: Article

References (34)

1. Shields R.L., Namenuk A.K., Hong K., Meng Y.G., Rae J., Briggs J., et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J Biol Chem 276 9 (2001) 6591-6604
2. Lazar G.A., Dang W., Karki S., Vafa O., Peng J.S., Hyun L., et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 103 11 (2006) 4005-4010
3. Weng W.-K., Stavenhagen J., Koenig S., and Levy R. Rituximab variants with re-engineered Fc with higher affinity to activating Fc gamma R eliminate the functional difference between Fc gamma R genotypes. Blood 106 11 (2005) 105A
4. Umana P., Jean-Mairet J., Moudry R., Amstutz H., and Bailey J.E. Engineered glycoforms of an anti-neuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17 (1999) 176-180
5. Shields R.L., Lai J., Keck R., O'Connell L.Y., Hong K., Meng Y.G., et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J Biol Chem 277 30 (2002) 26733-26740
6. Shinkawa T., Nakamura K., Yamane N., Shoji-Hosaka E., Kanda Y., Sakurada M., et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharide shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278 5 (2003) 3466-3473
7. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIII gene. Blood 99 3 (2002) 754-758
8. Weng W.-K., and Levy R. Two immunoglobulin G Fc receptor polymorphisms independently predict response to rituximab inpatients with follicular lymphoma. J Clin Oncol 21 (2003) 3940-3947
9. Alegre M.-L., Collins A.M., Pulito V.L., Brosius R.A., Olson W.C., Zivin R.A., et al. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody. J Immunol 148 11 (1992) 3461-3468
10. Bolt S., Routledge E., Lloyd I., Chatenoud L., Pope H., Gorman S.D., et al. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 23 (1993) 403-411
11. Cole M., Anasetti C., and Tso J.Y. Human IgG2 variants of chimeric anti-CD3 are non-mitogenic to T cells. J Immunol 159 (1997) 3613-3621
12. Bruggemann M., Williams G.T., Bindon C.I., Clark M.R., Walker M.R., Jefferis R., et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 166 5 (1987) 1351-1361
13. Steplewski Z., Sun L.K., Shearman C.W., Ghrayeb J., Daddona P., and Koprowski H. Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc Natl Acad Sci U S A 85 (1988) 4852-4856
14. Ngo C., Scallon B., McCabe F., Millar H., Nakada M., and Anderson M. Enhanced tumor inhibition of MDA-MB-231 breast carcinoma xenografts by the anti-tissue factor antibody, CNTO 860, is mediated by antibody dependent cellular cytotoxicity. J Immunother 27 6 (2004) S10
15. Isaacs J.D., Clark M.R., Greenwood J., and Waldmann H. Therapy with monoclonal antibodies: an in vivo model for the assessment of therapeutic potential. J Immunol 148 (1992) 3062-3071
16. Kaneko Y., Nimmerjahn F., and Ravetch J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313 (2006) 670-673
17. Scallon B.J., Tam S.H., McCarthy S.G., Cai A.N., and Raju T.S. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 44 (2007) 1524-1534
18. Niwa R., Shoji-Hosaka E., Sakurada M., Shinkawa T., Uchida K., Nakamura K., et al. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 64 (2004) 2127-2133
19. Mechetina L.V., Najakshin A.M., Alabyev B.Y., Chikaev N.A., and Taranin A.V. Identification of CD16-2, a novel mouse receptor homologous to CD16/FcγRIII. Immunogenetics 54 (2002) 463-468
20. Nimmerjahn F., Bruhns P., Horiuchi K., and Ravetch J.V. FcγRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23 (2005) 41-51
21. Nimmerjahn F., and Ravetch J.V. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 310 (2005) 1510-1512
22. Sibéril S., de Romeuf C., Bihoreau N., Fernandez N., Meterreau J.-L., Regenman A., et al. Selection of a human anti-RhD monoclonal antibody for therapeutic use: impact of IgG glycosylation on activating and inhibitory FcγR functions. Clin Immunol 118 (2006) 170-179
23. Li J., Davis J., Bracht M., Carton J., Armstrong J., Gao W., et al. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody. Int Immunopharmacol 6 (2006) 880-891
24. Kilmartin J.V., Wright B., and Milstein C. Rat monoclonal antitubulin antibodies derived by using a new nonsecreting rat cell line. J Cell Biol 93 (1982) 576-582
25. Knight D.M., Trinh H., Le J., Siegel S., Shealy D., McDonough M., et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30 (1993) 1443-1453
26. Papac D.I., Wong A., and Jones A.J. Analysis of acidic oligosaccharides and glycopeptides by matrix-associated laser desorption/ionization time-of-flight mass spectrometry. Anal Chem 68 (1996) 3215-3223
27. Papac D.I., Briggs J.B., Chin E.T., and Jones A.J. A high-throughput microscale method to release N-linked oligosaccharides from glycoproteins for matrix-assisted laser desorption/ionization time-of-flight mass spectrometric analysis. Glycobiology 8 (1998) 445-454
28. Raju T.S., Briggs J.B., Borge S.M., and Jones A.J. Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 10 (2000) 477-486
29. Alegre M.-L., Peterson L.J., Xu D., Sattar H.A., Jeyarajah D.R., Kowalkowski K., et al. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 57 (1994) 1537-1543
30. Galfre G., Milstein C., and Wright B. Rat × rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG. Nature 277 (1979) 131-133
31. Ferrara C., Stuart F., Sondermann P., Brünker P., and Umaña P. The carbohydrate at FcγRIIIa Asn-162. J Biol Chem 281 8 (2006) 5032-5036
32. Hamaguchi Y., Xiu Y., Komura K., Nimmerjahn F., and Tedder T.F. Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med 203 (2006) 743-753
33. Dijstelbloem H.M., van de Winkel J.G.J., and Kallenberg C.G.M. Inflammation in autoimmunity: receptors for IgG revisited. Trends Immunol 22 9 (2001) 510-516
34. Armour K.L., van de Winkel J.G.J., Williamson L.M., and Clark M. Differential binding to human FcRγIIa and FcRγIIb receptors by human IgG wildtype and mutant antibodies. Mol Immunol 40 (2003) 585-593